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Abstract
This paper proposes dynamic treatment regimes (DRTs) for choosing individualized effective treatment
strategies of chronic periodontitis. The proposed DTRs are studied via SMARTp – a two-stage sequential mul-
tiple assignment randomized trial (SMART) design. For this design, we propose a statistical analysis plan and
a novel cluster-level sample size calculation method that factors in typical features of periodontal responses,
such as non-Gaussianity, spatial clustering, and non-random missingness. Here, each patient/subject is viewed
as a cluster, and a tooth within a subject’s mouth is viewed as an individual unit inside the cluster, with the
tooth-level covariance structure described by a conditionally autoregressive process. To accommodate possible
skewness and tail behavior, the tooth-level clinical attachment level (CAL) response is assumed to be skew-t,
with the non-randomly missing structure captured via a shared parameter model corresponding to the missing-
ness indicator. The proposed method considers mean comparison for the regimes with or without sharing an
initial treatment, where the expected values and corresponding variances or covariance for the sample means of
a pair of DTRs are derived by the inverse probability weighting and method of moments. Simulation studies
are conducted to investigate the finite-sample performance of the proposed sample size formula under a variety
of outcome-generating scenarios. A major contribution of this work is the implementation of the sample size
formula via a R package available in GitHub.
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1 Introduction
Chronic periodontitis (CP) is a serious form of periodontal disease (PD), and if left untreated, continues to remain
a major cause of adult tooth loss (Eke et al., 2012). It is a highly prevalent condition, affecting almost half of
the US adults, ≥ 30 years (Thornton-Evans et al., 2013). Periodontal disease (PD) maybe exhibit significant
comorbidity, with diabetes, cardiovascular complications, respiratory illnesses, etc (Grossi et al., 1997; Wang
et al., 2009; Beck et al., 2001). Dental hygienists consider the Clinical Attachment Level (or, CAL), rounded
to the nearest millimeter, as the most important biomarker to measure the severity of PD (Nicholls, 2003). The
CAL refers to the amount of lost periodontal ligament fibers, with the severity categorized as Slight/Mild: 1-
2mm, Moderate: 3-4mm, Severe: ≥ 5mm, according to the American Academy of Periodontology (AAP) 1999
guidelines (Wiebe and Putnins, 2000).
The treatment options for periodontitis range from oral hygiene, to scaling and root planing (SRP), to SRP with
adjunctive treatments, and eventually to surgeries, when the severity increases. Recommended bi-annual (basic)
dental cleaning, polishing, and professional flossing which we enjoy sitting in a comfortable reclining chair in a
dental clinic only removes plaque (bacterial colony) and tartar above the gum line, and are not considered as effec-
tive procedures for treating gum diseases. Often, early stages of CP are effectively treated via non-surgical means.
Benefits of non-surgical treatment of CP includes shorter recovery time due to less-invasive techniques, reduced
discomfort than surgery, and fewer dietary restrictions leading to improved quality of life, post procedure. When
disease has progressed significantly, deep cleaning, a two-step process consisting of scaling and (tooth) root plan-
ning (SRP), is often recommended as the gold standard (Herrera, 2016) for thorough plaque removal, at or below
the gum line. Yet, bacteria may still exist under the gum line following a SRP. Hence, the dentist or oral hygienist
may also recommend various supplementary procedures, or adjuncts (such as locally-delivered antimicrobials, sys-
temic antimicrobials, non-surgical lasers, etc) following SRP to treat chronically deep gum pockets. Also, patients
with periodontal co-morbidity who responds sub-optimally to SRP may benefit from adjunctive therapy (Porteous
and Rowe, 2014). However, current evidence suggests that the use of these adjuncts as stand-alone treatments does
not lead to any clinical benefits of treating CP, compared to SRP alone (Azarpazhooh et al., 2010; Sgolastra et al.,
2012). Hence, they are usually recommended in conjunction to SRP.
In 2011, the Council on Scientific Affairs of the American Dental Association (ADA) resolved to develop a
Clinical Practice Guideline (CPG) for the non-surgical treatment (Smiley et al., 2015) of CP with SRP, with or
without adjuncts, based on a systematic literature review. The panel found 0.5 mm average improvement in CAL
with SRP, while the combination of SRP with assorted adjuncts resulted in (average) CAL improvement of 0.2-
0.6 mm, over SRP alone. However, comparison among the adjuncts were not conducted. Recently, a systematic
network meta-analyses (NMA) of the adjuncts in 74 studies from the CPG revealed none of them to be statistically
(significantly) superior to the other (John et al., 2017). However, the NMA ranked SRP + doxycycline hyclate gel (a
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local antimicrobial)’ as the best non-surgical treatment of CP, compared to SRP alone. Throughout the years, lasers
have revolutionized oral care, with reported advantages in minimizing tissue damages, swelling, and bleeding,
leading to high patient acceptance. However, it’s clinical efficacy, both as an alternative, or adjuvant to SRP
(Liu et al., 1999; Zhao et al., 2014) remains inconclusive, with inconsistent evidence derived from underpowered
clinical studies (Porteous and Rowe, 2014); see also the April 2011 statement (Workgroup, 2011) by the AAP.
Although (randomized) clinical trials (RCT) and subsequent meta-analyses continue to remain the de facto in
understanding effectiveness of a treatment (or intervention) over others, conducting a successful RCT comes with
its own bag of limitations, which includes issues with patient recruitment and retention, escalating costs, educating
the wider public, etc. This has led to the development of more patient-centric approaches, primarily through
adaptive interventions, or dynamic treatment regimes (DTR) (Murphy et al., 2001; Murphy, 2003; Robins, 2004)
under the umbrella of precision medicine (Garcia et al., 2013), where the focus changed to decision-making for
the individual, or subgroups, rather than average-response based traditional RCT treatment comparisons. DTRs
involve multistage sequential interventions, according to the patients’ evolving characteristics (such as patient’s
response, or adherence) at each subsequent treatment stage. The treatment types are repeatedly adjusted over time
to match an individual’s need in order to achieve optimal treatment effect. They are very appealing in managing
chronic diseases that require long-term care (Lavori and Dawson, 2004; Murphy and McKay, 2004). Examples of
DTRs from various clinical areas include alcoholism (Breslin et al., 1998), smoking cessation (Chakraborty et al.,
2010), drug abuse (Brooner and Kidorf, 2002), depression (Untzer et al., 2001), hypertension (Glasgow et al.,
1989), etc. However, in the field of oral health and CP, a DTR proposal to mitigate the aforementioned issues
related to RCTs seem to be non-existent. For example, in the treatment of CP, one may develop a simple adaptive
strategy of continuing the SRP (in the later stages) among the SRP responders-only group (in the first stage), while
subjecting the non-responders to ‘SRP + adjuncts’ at later stages.
A special class of designs, called Sequential Multiple Assignment Randomized Trial, or SMART designs
(Murphy, 2005; Lei et al., 2012) are popularly used to study DTRs (Chakraborty and Moodie, 2013). SMART
designs involve randomizing patients to available treatment options at the initial stage, followed by re-randomizing
at each subsequent stage of some or all of the patients to treatments available at that stage. These re-randomizations
and set of treatment options depend on how well the patient responded to the previous treatments (Ghosh et al.,
2016). Contrary to the standard RCT that takes a ‘one size fits all’ single intervention approach, the SMART
advances the RCT by following the same individual over sequential randomizations (i.e., ordered interventions)
with the underlying series and order of interventions depicting a real-life setting, that can drastically affect eventual
outcomes. Although Murphy (2005) proposed the general SMART design framework, the treatment was restricted
to individual-level outcomes. However, in our motivating clinical discipline of treating CP (and in other behavioral
intervention research), interventions are delivered at the group, or cluster (individual) level, while the CAL re-
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sponses are available at the cluster sub-unit level (teeth) level. Although sample size formulas and SMART design
implementations under clustered outcomes setting are available (Ghosh et al., 2016; NeCamp et al., 2017), they
only focus on regimes that do not share an initial treatment. Furthermore, they do not account for other data com-
plications typical to PD studies, such as presence of (i) non-Gaussian (skewed and thick-tailed), (ii) non-randomly
missing, and (iii) spatially-referenced CAL responses (Reich et al., 2013). For example, consider the motivating
GAAD data, which recorded the extent of PD in a Type-2 diabetic Gullah-speaking African American population
from the coastal South Carolina sea-islands (Fernandes et al., 2009). For illustration, panel (a) in Figure 1 describe
the measurement locations and sample data for a random subject, while panel (b) plots the density histogram of
the CAL for the four tooth-types from the GAAD dataset, revealing considerable right-skewness. Furthermore,
PD being the major cause of adult tooth-loss, it is likely that patients with higher level of CAL (and CP) exhibit
a higher proportion of missing teeth, and hence this missingness mechanism is non-ignorable (Reich et al., 2013).
Also, CP and PD are hypothesized to be spatially-referenced, i.e., proximally located teeth usually have similar
disease status than distally located ones. Ignoring the features (i)–(iii) in constructing any SMART design for CP
may lead to imprecise estimates of the desired parameters. It is important to note here that the Ghosh et al. (2016)
approach of a clustered SMART design considers traditional clustering (sub-units within a cluster) of Gaussianly
distributed continuous responses, and excludes spatial clustering and other features.
In this paper, we set forward to address the aforementioned limitations in developing a list of plausible DTRs
for treating CP. We cast this into a two-stage SMART design framework for CP outcomes that exhibit (i)–(iii),
and present an analysis plan and sample size calculations for (a) detecting a postulated effect size of a single
treatment regime, and (b) detecting a postulated difference between two treatment regimes with or without a shared
initial treatment. The tooth-level covariance structure describing spatial-association is modeled by a conditionally
autoregressive process (Reich and Bandyopadhyay, 2010). To accommodate possible skewness and tail behavior,
the tooth-level CAL responses are assumed to have skew-t (Azzalini and Capitanio, 2003a) errors, with the non-
randomly missing CAL values imputed via a shared parameter model corresponding to the missingness indicator.
The proposed method considers mean comparison for the regimes with or without sharing an initial treatment,
where the expected values and corresponding variances or covariance of the effect size of the treatment regimes
are derived by the inverse probability weighting (IPW) techniques (Robins et al., 1994b), and method of moments.
The rest of the paper is organized as follows. Section 2 introduces eight potential treatment, and the cor-
responding DTRs that constitute the 2-stage SMART design for CP. Section 3 presents the theoretical frame-
work and a sample size calculation method under this SMART design, incorporating the aforementioned fea-
tures typical to PD data. Section 4 investigates the finite-sample performance of the proposed sample size cal-
culation method using synthetic data generated under various settings. Section 5 demonstrates the implementa-
tion of the R function SampleSize.SMARTp for calculating sample sizes, also available at the GitHub link
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Figure 1: CAL data. Panel (a) shows the observed CAL for a patient with a missing incisor, where the shaded
boxes represent teeth, the circles represent sites, and gray lines represent neighbour pairs that connects adjacent
sites on the same tooth and sites that share a gap between teeth. “Gap” in the figure indicates, for example, the
four sites in the gap between teeth # 4 and 5. The tooth numbers are indicated, and excludes the 4 third-molars: 1,
16, 17 32. The vertical and horizontal lines separate the mouth into four quadrants, with the molars (# 2-3, 14-15,
18-19, 30-31), premolars (# 4-5, 12-13, 20-21, 28-29), canines (# 6, 12, 22, 27) and incisors (# 7-10, 23-26). Panel
(b) presents the frequency density plot of the CAL (rounded to the nearest mm) for each tooth type from the GAAD
dataset.
https://github.com/bandyopd/SMARTp. Finally, the paper ends with a discussion in Section 6. Sup-
plementary Material, consisting of detailed derivations are relegated to the Appendix.
2 A SMART design for the DTRs
In this section, we propose dynamic treatment regimes (DTRs) for treating CP, which are studied via a SMART
design. A list of possible treatments consist of the treatment initiation steps: (1) Oral hygiene instruction, and (2)
Education on risk reduction. This is followed by (3) SRP, or more advanced non-surgical treatments that combine
SRP with adjunctive therapy, as summarized in the systematic review of Smiley et al. (2015), such as (4) SRP
with local antimicrobial therapy, (5) SRP with systemic antimicrobial therapy, (6) SRP with photodynamic ther-
apy, which uses lasers, but only to activate an antimicrobial agent), (7) SRP with systemic subantimicrobial-dose
doxycycline (SDD), and finally, (8) Laser. The corresponding SMART design for developing DTRs is presented in
Figure 2. Note that the number of potential DTRs are not limited to Figure 2. More details are presented in Section
6.
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Figure 2: A SMART design diagram for developing DTRs treating chronic periodontitis. R=randomization, 1=oral
hygiene instruction, 2=education on risk reduction, 3=scaling and root planing (SRP), 4=SRP with local antimicro-
bial therapy, 5=SRP with systemic antimicrobial therapy, 6=SRP with photodynamic therapy, 7=SRP with systemic
sub-antimicrobial-dose doxycycline (SDD), 8=laser therapy.
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Oral hygiene is primarily used for prevention and initial therapy, especially during early stage of periodontitis.
At the beginning of the proposed trial, each participant has to attend the treatment initiation steps (1) and (2) before
any randomization. Note that while SRP is the accepted gold-standard, the role of laser therapy, though advanta-
geous in targeting the diseased area precisely and accurately, still remains controversial as a standard of care. In
this paper, we develop our SMART design, with a primary focus on comparing the DTRs starting with either SRP
(# 3), or Laser therapy (# 8). At the initial stage, each participant is randomly allocated to either treatment 3 or 8.
We propose a DTR that matches an patient’s’s need in achieving similar outcome as SRP with adjuncts, though at
a lower cost. Each possible treatment regime can have more than one path of treatment according to each patient’s
evolving response. The patients who respond to the initial treatment continue the same treatment at the 2nd stage
of the trial. The patients who do not respond to treatment 3 are randomly allocated to one of the treatments 4–7 in
the 2nd stage. Similarly, for patients allocated to the laser arm (treatment 8), the non-responders will also have the
provision of being randomly allocated to one of 4–7 in the 2nd stage. The randomization probabilities calculated
at both the initial and final stages of our SMART design is presented in Section 3.3. The primary final outcome
measure is the recorded and rounded tooth-level CAL. The possible paths are listed below, i.e.
• Path 1: ‘1’, ‘2’, ‘3’, ‘3’
• Path 2: ‘1’, ‘2’, ‘3’, ‘4’
• Path 3: ‘1’, ‘2’, ‘3’, ‘5’
• Path 4: ‘1’, ‘2’, ‘3’, ‘6’
• Path 5: ‘1’, ‘2’, ‘3’, ‘7’
• Path 6: ‘1’, ‘2’, ‘8’, ‘8’
• Path 7: ‘1’, ‘2’, ‘8’, ‘4’
• Path 8: ‘1’, ‘2’, ‘8’, ‘5’
• Path 9: ‘1’, ‘2’, ‘8’, ‘6’
• Path 10: ‘1’, ‘2’, ‘8’, ‘7’
This leads to eight different DTRs (d1-d8) that are embedded within the two-stage SMART design, i.e.
Regime 1 (d1): (‘3’,‘3’R,‘4’NR)
Regime 2 (d2): (‘3’,‘3’R,‘5’NR)
Regime 3 (d3): (‘3’,‘3’R,‘6’NR)
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Regime 4 (d4): (‘3’,‘3’R,‘7’NR)
Regime 5 (d5): (‘8’,‘8’R,‘4’NR)
Regime 6 (d6): (‘8’,‘8’R,‘5’NR)
Regime 7 (d7): (‘8’,‘8’R,‘6’NR)
Regime 8 (d8): (‘8’,‘8’R,‘7’NR)
Here, Regime 1 can be explained as following treatments 1 and 2, a patient undergoes treatment 3 (considered
as treatment at initial stage). If that patient responds (R) to the initial treatment, he or she continues with treatment
3 at 2nd stage, while a non-responder (NR) will receive treatment 4 at the 2nd stage. The other regimes can be
explained similarly. There are a number of advantages (Chakraborty and Moodie, 2013) of SMART designs over
a series of single-stage trials to develop an optimal DRT. First, the single-stage trials may fail to detect the delayed
effect. For example, the patients who respond to laser therapy may achieve better outcomes than those who respond
to SRP initially, however, the effectiveness of the SRP may be realized in the later stages (here, 2nd stage) when
possible adverse events may occur due to laser therapy. Second, the single-stage trials may also fail to detect the
diagnostic effect. Based on the patients’ treatment outcome at initial stage, e.g., laser therapy, the SMART design
could allocate the right treatment at final stage depending on participants’ response, e.g., the non-responders of
laser therapy receive SRP with one of the adjuncts, e.g, systematic anti-microbial at final stage. Third, single-stage
trials may result in possible cohort effect. The non-responding patients who are treated by SRP at initial stage
may drop out of single-stage trials, which could incur biased estimation of treatment effect. Under the proposed
SMART design, participants expect to receive better treatments, i.e. SRP with adjuncts, at the next stage, if SRP is
not effective initially.
3 SMART Design: Model, Hypothesis Testing and Sample Size Calculations
In this section, we propose the theoretical framework and a novel sample size formula for our SMART design.
3.1 Statistical Model
We start with introducing some notations. Let Ai1 denote the treatment for patient i at the initial stage (i.e. ‘3’ or
‘8’); Ri(Ai1) denote the proximal response after initial treatment Ai1, i.e Ri(·) = 1 if the ith patient is a responder
and Ri(·) = 0 otherwise; Ai2(Ai1, Ri(Ai1)) denote the treatment at final stage based on initial (first) stage treat-
ment and response; Yit denote the final outcome measure, i.e. change in mean CAL for the tth teeth of patient i;
Mit denotes the missingness indicator of the tth teeth of patient i, i.e. Mit = 1 if missing, or 0 otherwise. Thus,
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the observed data trajectory for patient i can be described as Oi=(Ai1, Ri(Ai1), Ai2(Ai1, Ri(Ai1)), Yi,1,. . .,Yi,28,
Mi,1,. . .,Mi,28). Note that we have N patient in the sample, and each patient has a maximum of 28 teeth (if no
tooth is missing). Thus, the (overall) outcome measure for patient i is Y¯i =
∑28
t=1 Yit(1−Mit)/
∑28
t=1(1−Mit),
which is the mean of CAL of the available teeth for patient i. Hence the proportion of the available teeth for patient
‘i’ is pˆi =
∑28
t=1(1−Mit)/28. The regression model for Y is given by:
Yit = µi +Qit + it1, (1)
for i = 1, . . . , N and t = 1, . . . , 28, where µi = β0 + β1Ai13 + β2Ai13Ri + β3Ri + β4Ai13Ai24(1 − Ri) +
β5Ai13Ai25(1 − Ri) + β6Ai13Ai26(1 − Ri). Here, Ai13 is an indicator of treatment ‘3’ at initial stage for patient
i, Ai24 is an indicator of treatment ‘4’ at final stage for patient i, and it1 is the (random) error term distributed
as a skew-normal (SN(, or skew-t (ST) density (Azzalini and Capitanio, 2003b), i.e., it1 ∼ ST (0, σ21, λ, ν),
with location parameter 0, scale parameter σ1, skewness parameter λ, and degrees of freedom ν that measure
the kurtosis. Note, the distribution of it1 is normal if λ = 0 and ν = ∞, skew-normal if λ 6= 0 and ν = ∞,
t if λ = 0 and ν < ∞, and skew-t, if λ 6= 0 and ν < ∞. Expressions of the mean, variance, skewness γ1
and kurtosis γ2 for both SN and ST distributions are presented in Appendices A and B respectively. Following
Reich et al. (2013), we assume the latent vector Qi=(Qi1, . . . , Qi28)
> follows a multivariate normal distribution,
with mean vector 028×1 and covariance matrix Σ28×28 with a conditional autoregressive (CAR) structure, i.e.
Σ28×28 = τ2(C28×28 − ρD28×28)−1. Here, τ2 > 0 and ρ ∈ [0, 1] are the parameters controlling the magnitude
of variation, and degree of spatial association, respectively. For matrixD, the elements Dtt′ are ones if locations t
and t′ are adjacent, and zeroes otherwise. The matrix C is diagonal with diagonal elements Ctt =
∑
t′ Dtt′ .
Next, under the assumption of non-randomly missing teeth (locations of missing teeth are not random, but
rather related to the CP health in that region of the mouth), we propose a probit regression model for the missing
teeth indicator as a function of the underlying (spatial) latent term Qi. Define Mit = I(Mit0 > 0), where Mit0 is
a (latent) continuous variable, modeled as:
Mit0 = a0 + b0Qit + it0, (2)
where it0
i.i.d∼ N(0, σ20). For sake of identifiability, we choose σ20 = 1. Here, under the popular shared-
parameter framework (Vonesh et al., 2006), Q facilitates sharing of information between Y and M for mod-
eling non-randomly missing data. The parameters a0, b0, and the estimates Qi and it0 determine the pro-
portion of available tooth pi = E(pˆi), which can be estimated using either stochastic or deterministic method
(see Appendix C). The parameter b0 controls the association between Y and M , e.g., b0 = 0 indicates
no association. For example, the Pearson correlation coefficient between Yit and Mit0 (from (2)) is cit =
9
b0var(Qit)/
√
(var(Qit) + var(it1))(b20var(Qit) + var(it0)), see Appendix C for the derivation. For power anal-
ysis, one may choose the distributions of Qi, it1 and it0 from the literature, e.g., Reich and Bandyopadhyay
(2010). Define ci=
∑
t cit/28. The clinician may suggest values for µi, pi and ci, and the corresponding estimates
of a0 and b0 can be obtained by solving aa set of simultaneous equations involving pi and ci.
Next, we derive the expected value and variance for the sample mean of a DTR, using d1 as an example, based
on the IPW principle. IPW techniques have been successfully applied for estimating regression coefficients (Robins
et al., 1994a), and population mean (Cao et al., 2009), in the context of incomplete data. For DTRs under SMART
designs, most likely, we are unable to sample data directly from a particular regime. For example, responders of
SRP can be classified as either regimes 1-4. Hence, a method of moments estimate of the sample mean for regime
1 is given by:
Y¯ d1 = Ed1(Y¯i) = E
(
W d1i Y¯i
)
, (3)
where
W d1i =
I(Ai1 = a
d1
1i , Ai2 = [a
d1R
2i ]
Ri [ad1NR2i ]
1−Ri)
pid11i [pi
d1R
2i ]
Ri [pid1NR2i ]
1−Ri
. (4)
where, Y¯i: the final outcome measure of CAL change for patient i; I(·): indicator function; Ri: binary response
indicator for treatment ‘3’ at initial stage; ad11i : the regime 1 (d1) treatment at initial stage for patient i, e.g., ‘3’;
ad1R2i : regime 1 treatment at final stage if participant i is a responder (i.e. Ri = 1), e.g., ‘3’; a
d1NR
2i : regime
1 treatment at final stage if patient i is a non-responder (i.e. Ri = 0), e.g., ‘4’; pid11i : probability of treatment
allocation of regime 1 at initial stage for patient i; pid1R2i : probability of treatment allocation of regime 1 at final
(2nd) stage if patient i is a responder, i.e. 1; pid1NR2i : probability of treatment allocation of regime 1 at final stage,
if patient i is a non-responder, i.e. 1/4.
To maximize power, we estimate pid11i as in (Murphy, 2005) to have equal sample sizes across all possible
regimes. We set
pid11i =
(1 · γd1 + 1
4
· (1− γd1))−1
(1 · γd1 + 1
4
· (1− γd1))−1 + (1 · γd5 + 1 · (1− γd5))−1
, (5)
where γd1 denotes the response rate for regime 1 at initial stage. If γd1 and γd5 are not known, we set
pid11i =
max(1−1,
1
4
−1
)
max(1−1,
1
4
−1
) + max(1−1, 1−1)
. (6)
Alternatively, we set pid11i = 1/2, if equal probability of treatment allocation at initial stage is required.
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The mean and variance of Y¯ d1 are derived below. We have
E(Y¯ d1) = E(
I(Ai1 = a
d1
1i , Ai2 = [a
d1R
2i ]
Ri [ad1NR2i ]
1−Ri)
pid11i [pi
d1R
2i ]
Ri [pid1NR2i ]
1−Ri
Y¯i), (7)
var(Y¯ d1) =
1
N
var(
I(Ai1 = a
d1
1i , Ai2 = [a
d1R
2i ]
Ri [ad1NR2i ]
1−Ri)
pid11i [pi
d1R
2i ]
Ri [pid1NR2i ]
1−Ri
Y¯i). (8)
In terms of pi, γ, µ and σ, (7) and (8) can be expressed alternatively as
E(Y¯ d1) = γd1µd1R + (1− γd1)µd1NR = µd1
and
V (Y¯ d1)
=
1
N
{ γ
d1
pid11i [pi
d1R
2i ]
(σ2d1R + (1− pid11i [pid1R2i ])µ2d1R)+
1− γd1
pid11i [pi
d1NR
2i ]
(σ2d1NR + (1− pid11i [pid1NR2i ])µ2d1NR)+
γd1(1− γd1)(µd1R − µd1NR)2},
where σ2d1R: the variance of Y¯i from d1 and Ri = 1; µd1R: the mean of Y¯i from d1 and Ri = 1. Detailed
expressions of both σ2d1R and µd1R appear in Appendix C. However, we compute them using Monte Carlo method.
Likewise, both E( ¯Y d3) and V (Y¯ d3) can be derived; see Appendix C.
3.2 Hypothesis Testing
Our SMART design allows the following three important hypothesis tests:
1. Detecting a single DTR effect on CAL, e.g., H0 : µd1 = 0 vs H1 : µd1 = δd1 6= 0;
2. Comparing two DTRs that share an initial treatment, i.e. DTRs with SRP and adjuncts, e.g., H0 : µd1 −
µd3 = 0 vs H1 : µd1 − µd3 = δd1−d3 6= 0;
3. Comparing two treatment DTRs that do not share an initial treatment, i. e. the DTRs initialized by SRP and
laser, e.g. H0 : µd1 − µd5 = 0 vs H1 : µd1 − µd5 = δd1−d5 6= 0.
11
Hypothesis 1 can be used to test whether the improvement in CAL in the proposed DTR is better than SRP
(e.g., ≥ 0.5mm), or not worse than SRP with adjuncts (e.g., 0.7–1.1 mm), based on the systematic review results
of Smiley et al. Smiley et al. (2015). Since the network meta-analyses by John et al. John et al. (2017) found
no significant evidence of CAL improvement among adjuncts, Hypothesis 2 can be used to test if indeed there are
statistically significant differences between the DTRs of SRP and ‘SRP + adjuncts’. The treatment effect of laser
therapy is still under investigation; we can use Hypothesis 3 to test if there is a statistically significant difference
between the DTRs initialized by SRP and laser.
Consider Hypothesis 2. The Expectation and variance of regimes difference can be expressed respectively as
E(Y¯ d1 − Y¯ d3) = µd1 − µd3 = δd1−d3 (9)
and
V (Y¯ d1 − Y¯ d3) = V (Y¯ d1) + V (Y¯ d3)− 2COV (Y¯ d1 , Y¯ d3) = 1
N
2σ2d1−d3 . (10)
Note, both δ and σ2 in equations (9) and (10) respectively are functions of the parameter vector Ωd1−d3=(µ, τ ,
ρ, λ, ν, σ21 , σ
2
0 , a0, b0, γ
d1 , pid11 , pi
d1R
2 , pi
d1NR
2 , γ
d3 , pid31 , pi
d3R
2 , pi
d3NR
2 ). Note, µ, τ , ρ, λ, ν, σ
2
1 , σ
2
0 , a0 and b0 are
defined in equations (1) and (2), while parameters γ’s and pi’s are defined in equations (3) to (5). The covariance
between Y¯ d1 and Y¯ d3 is
COV
(
Y¯ d1 , Y¯ d3
)
=
1
N
{ γ
d1
pid11i pi
d1R
2i
(σ2d1R + µ
2
d1R)− γd1γd3µd1Rµd3R
− γd1(1− γd3)µd1Rµd3NR
− γd3(1− γd1)µd1NRµd3R
− (1− γd1)(1− γd3)µd1NRµd3NR}.
Note that γd1 = γd3 , µd1R = µd3R and σ
2
d1R
= σ2d3R, since the responders from treatment ‘3’ are consistent
with both the treatment regimes 1 and 3. The derivations of both E(Y¯ d1 − Y¯ d3) and V (Y¯ d1 − Y¯ d3) can be found
in Appendix C. We now present a theoretical result below; see it’s proof in Appendix D.
Theorem 1 The IPW and MOM estimator δˆd1−d3 is a consistent estimator of δd1−d3 . Under moment conditions
and following assumptions below, we have
√
N(δˆd1−d3 − δ(d1−d3)0)→ N(0, 2σ2d1−d3).
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Assumptions:
1. Random vectors (Y¯i, W d1i , W
d3
i ), 0 ≤ i ≤ N are independent and identically distributed, and distribution of
Y¯i is independent of W d1i and W
d3
i , where W
d1
i is defined by equation (4);
2. E(W d1i Y¯i − µd1) = 0, only when µd1 = µd10 and E(W d3i Y¯i − µd3) = 0 only when µd3 = µd30. Hence,
E(δˆd1−d3 − δd1−d3) = 0 only for δd1−d3 = δ(d1−d3)0=µd10 − µd30;
3. The possible sets for regime means and effect size µd1 , µd3 , δd1−d3 ∈ Θ are compact;
4. δˆd1−d3 − δd1−d3 is continuous at each δ, with probability one;
5. Esupδd1−d3∈Θ
(δˆd1−d3 − δd1−d3) <∞.
Though the regimes 1 and 5 do not share any initial treatments, the covariance between the sample mean
of these two regimes can be derived in the similar way as COV
(
Y¯ d1 , Y¯ d3
)
. The mathematical formula for
COV
(
Y¯ d1 , Y¯ d5
)
is given in Appendix C.
Before deriving the sample size formula, we present the test statistics for the corresponding hypotheses below.
For example, for H0 : µd1 − µd3 = 0 vs alternative H1 : µd1 − µd3 = δd1−d3 6= 0 (hypothesis 2), we use
the univariate Wald statistics Z = δd1−d3/
√
2σ2d1−d3/N , where δd1−d3 is the effect size and σ
2
d1−d3 is given in
(10). In large samples, Z follows a standard normal distribution if H0 is true. Hence, at α level of significance,
we reject H0 if | Z |> zα/2, where zα/2 is the upper α/2 quantile of a standard normal distribution. In a similar
way, the test statistic for Hypothesis 1 (H0 : µd1 = 0 vs H1 : µd1 = δd1 6= 0) and 3 (H0 : µd1 − µd5 = 0 vs
H1 : µd1 − µd5 = δd1−d5 6= 0) are Z = δd1/
√
2σ2d1/N and Z = δd1−d5/
√
2σ2d1−d5/N respectively, where both
follow standard normal distribution if H0 is true.
3.3 Sample size calculation
The calculated sample size is possible to detect the effect size of either a single regime or the difference between
two regimes. The proposed sample size formulas for Hypothesis tests 1-3 under our SMART design are given by
N = 2(zα/2 − z1−β)2
σ2d1
δ2d1
, (11)
N = 2(zα/2 − z1−β)2
σ2d1−d3
δ2d1−d3
(12)
and
N = 2(zα/2 − z1−β)2
σ2d1−d5
δ2d1−d5
(13)
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respectively, where σ2d1−d3 is defined by (10), and in the similar way, both σ
2
d1
and σ2d1−d5 can also be defined;
α =Pr(Type one error), β =Pr(Type two error)= 1 - Power, Pr(z > zα/2) = α/2 and Pr(z > z1−β) = 1−β, the ef-
fect size δd1−d3 = µd1 − µd3 . Therefore, we define the standardized effect size by δ∗d1−d3 = δd1−d3/σd1−d3 . Note,
our calculations advance the previous ones for SMART designs in clustered data (Ghosh et al., 2016; NeCamp
et al., 2017) by including non-Gaussianity, spatial association, and non-random missingness features, typical for
periodontal responses, in addition to considering comparisons between regimes that shares the same initial treat-
ment. Also, the patients (or clusters) are randomly allocated with equal probability for each regime, which requires
smaller sample size than allocation with equal treatment probability at each stage.
4 Simulation studies
We now present simulation studies to investigate the finite-sample performance of the proposed sample size for-
mulas (11) to (13) in terms of computing Monte Carlo power estimates based on 5000 simulated data sets, given
the type-II error rate β = 0.2, or nominal power of 80% and type-I error rate α = 0.05. We also compare the
theoretical and Monte Carlo mean and variance of the estimated effect sizes for the DTRs.
The Monte Carlo data generation steps are given below. These include generating the random variables Ai1,
Ri(Ai1) and Ai2(Ai1, Ri(Ai1)), Mit and Yit for each patient i, i = 1, . . . , N .
Step 1 The initial treatment Ai1 is assigned randomly to either ‘3’ or ‘8’, with probability pid11i and 1− pid11i respec-
tively.
Step 2 The response variable Ri(Ai1) is generated from Bernoulli(γd1) if Ai1=‘3’, or Bernoulli(γd5) if Ai1=‘8’,
where γd1 = 0.25 or 0.5 and γd5 = 0.5.
Step 3 The final treatment Ai2(Ai1 = ‘3’, Ri(Ai1 = ‘3’) = 1) is assigned to ‘3’ with probability of 1, and
Ai2(Ai1 = ‘3’, Ri(Ai1 = ‘3’) = 0) is randomly assigned to‘4’, ‘5’, ‘6’ or ‘7’ with probability of 1/4, while
Ai2(Ai1 = ‘8’, Ri(Ai1 = ’8’) = 1) is assigned to ‘8’ with probability 1 and Ai2(Ai1 = ‘8’, Ri(Ai1 =
’8’) = 0) is assigned to ‘4’, ‘5’, ‘6’ or ‘7’ with probability of 1/4.
Step 4 The change in mean CAL Yit and missingness indicatorMit of each tooth are generated by regression models
(1) and (2) respectively. For the model parameters, we assume τ = 0.85, ρ = 0.975, a0 = −1, b0 = 0.5,
σ1 = 0.95 and σ0 = 1 based on estimates from Bandyopadhyay and Reich (Reich and Bandyopadhyay,
2010). For model (1), we select µi = 0 if Ri = 1 and µi = 0.5, 2 or 5 if Ri = 0 to test the proposed method.
The skewness and kurtosis parameters for the error term it1 of model (1) are chosen as λ = 0, 2 and 10,
ν =∞, 10, 8 and 6. This choice of parameter estimates for model (2) give expected proportion of available
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teeth around 80% (i.e. pi ≈ 0.8) for each patient. Given the parameters of models (1) and (2), at λ = 10 and
ν = 6, the association between CAL change and missingness is around 0.44 (i.e. ci ≈ 0.44).
Step 5 The mean CAL change for patient i is computed as Y¯i =
∑28
t=1 Yit(1−Mit)∑28
t=1(1−Mit)
.
Tables 1 - 3 present a list of sample sizes calculated by the proposed method, with the corresponding Monte
Carlo powers based on hypotheses 1-3, respectively. Various pairs of the skewness and kurtosis parameter (λ, ν)
corresponding to the error it1 are selected. Recall, λ = 0 and ν = ∞ indicates normal distribution; λ 6= 0 and
ν = ∞ indicates skew-normal distribution; λ = 0 and ν < ∞ indicates t distribution, and λ 6= 0 and ν < ∞
indicates skew-t distribution. We consider a list of effect sizes δd1 (i.e. µd1), and present their corresponding
absolute values | δd1 |, Monte Carlo estimates | δˆd1 |, standard deviations (i.e. ESD(δd1)), and the Monte Carlo
standard deviations (i.e., MCSD(δd1)). We define µi = 0 if Ri = 1 and µi = 2 (e.g., the first row), or 5 (e.g.,
the second row) if Ri = 0 for regime 1. The absolute value of the standardized effect size is calculated as
| δ∗d1 |=| δd1/σd1 |. We obtain small to medium (0.2-0.5) and medium to large (0.5-0.8) absolute standardized
effect sizes. The results show that the Monte Carlo estimated powers (78%− 82%) are close to the nominal power
based on the sample size formula (11), while the estimated mean and standard deviation of the effect sizes are very
close to the corresponding Monte Carlo estimates.
Simulation results corresponding to hypotheses 2 and 3 are presented in Tables 2 and 3 respectively. They
are similar to the results of Table 1. The Monte Carlo estimates of power are close to 80%, while the mean and
standard deviation of δˆd1−d3 or δˆd1−d5 are very close to the corresponding theoretical estimates. Note, Table 2
compares regimes 1 and 3. This comparison includes a pair of regimes that shares treatment ‘3’, where we define
µi = 0 if Ri = 1 and µi = 0.5 if Ri = 0 for regime 1, while we define µi = 0 if Ri = 1 and µi = 2 or 5 if
Ri = 0 for regime 3. For example, in the first two rows, | δd1−d3 |= 1.13 corresponds to µi = 2 for regime 3
when Ri = 0, while | δd1−d3 |= 3.38 corresponds to µi = 5 for regime 3 when Ri = 0. Finally, Table 3 compares
regimes 1 and 5, where we define µi = 0 if Ri = 1 and µi = 0.5 if Ri = 0 for regime 1, while we define µi = 0
if Ri = 1 and µi = 2 or 5 if Ri = 0 for regime 5, e.g., the first row corresponds to µi = 2 while the second row
corresponds to µi = 5 for regime 5 when Ri = 0.
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Table 1: Estimated Sample size (Nˆ ) and the Monte Carlo estimated power (Pˆ ) at β = 0.2 and α = 0.05, based
on hypothesis test of H0 : µd1 = 0 versus H1 : µd1 6= 0, under different absolute value of effect size (| δd1 |)
with the corresponding Monte Carlo effect size (| δˆd1 |), standard deviation (ESD(δd1)) and Monte Carlo standard
deviation (MCSD(δd1)), absolute value of standardized effect size (| δ∗d1 |) and treatments ‘3’ response rate(γd1),
skewness parameter (λ) and degree of freedom (ν), given treatment ‘8’ response rate γd5 = 0.5, σ1 = 0.95,
σ0 = 1, ρ = 0.975, τ = 0.85, expected % available teeth per patient pi = 80%.
| δd1 | | δˆd1 | λ ν γd1 ESD(δd1 ) MCSD(δd1 ) | δ∗d1 | Nˆ Pˆ
1.32 1.32 0 Inf 0.25 0.47 0.47 0.45 78.00 0.80
3.57 3.56 1.27 1.25 0.49 67.00 0.79
0.82 0.81 0.5 0.29 0.29 0.31 169.00 0.80
2.32 2.34 0.83 0.83 0.35 131.00 0.80
1.99 1.99 2 0.25 0.71 0.70 0.52 59.00 0.80
4.24 4.25 1.50 1.51 0.51 61.00 0.81
1.49 1.50 0.5 0.53 0.53 0.43 87.00 0.80
3.00 2.99 1.07 1.07 0.40 100.00 0.78
2.07 2.07 10 0.25 0.74 0.74 0.52 58.00 0.79
4.32 4.35 1.54 1.54 0.51 60.00 0.82
1.57 1.57 0.5 0.56 0.55 0.44 83.00 0.79
3.07 3.08 1.09 1.08 0.40 98.00 0.80
1.32 1.33 0 10 0.25 0.47 0.47 0.45 78.00 0.80
3.57 3.56 1.27 1.25 0.49 67.00 0.79
0.82 0.82 0.5 0.29 0.29 0.30 170.00 0.80
2.32 2.31 0.83 0.83 0.35 131.00 0.79
1.32 1.31 8 0.25 0.47 0.47 0.45 78.00 0.79
3.56 3.56 1.27 1.28 0.49 67.00 0.78
0.82 0.82 0.5 0.29 0.29 0.30 170.00 0.80
2.32 2.30 0.83 0.83 0.35 131.00 0.79
1.32 1.31 6 0.25 0.47 0.47 0.45 78.00 0.79
3.56 3.57 1.27 1.26 0.49 67.00 0.79
0.82 0.82 0.5 0.29 0.29 0.31 169.00 0.79
2.31 2.30 0.83 0.83 0.35 131.00 0.79
2.05 2.06 2 10 0.25 0.73 0.73 0.52 58.00 0.80
4.30 4.25 1.53 1.53 0.51 60.00 0.78
1.55 1.55 0.5 0.55 0.56 0.43 84.00 0.79
3.05 3.05 1.09 1.08 0.40 98.00 0.79
2.07 2.07 8 0.25 0.74 0.74 0.52 58.00 0.80
4.32 4.35 1.54 1.54 0.51 60.00 0.81
1.57 1.57 0.5 0.56 0.55 0.44 83.00 0.81
3.07 3.07 1.09 1.10 0.40 98.00 0.79
2.10 2.08 6 0.25 0.74 0.74 0.52 58.00 0.79
4.35 4.36 1.54 1.55 0.51 60.00 0.81
1.60 1.59 0.5 0.57 0.56 0.44 82.00 0.79
3.10 3.08 1.10 1.10 0.40 97.00 0.79
2.13 2.13 10 10 0.25 0.76 0.76 0.53 57.00 0.79
4.38 4.37 1.55 1.55 0.52 60.00 0.81
1.63 1.63 0.5 0.58 0.58 0.44 80.00 0.80
3.13 3.13 1.11 1.12 0.41 96.00 0.79
2.15 2.16 8 0.25 0.76 0.77 0.53 57.00 0.80
4.40 4.42 1.57 1.59 0.52 59.00 0.80
1.65 1.64 0.5 0.59 0.58 0.45 80.00 0.80
3.15 3.16 1.12 1.13 0.41 95.00 0.80
2.18 2.19 6 0.25 0.77 0.78 0.53 57.00 0.80
4.43 4.45 1.58 1.58 0.52 59.00 0.80
1.68 1.68 0.5 0.60 0.60 0.45 78.00 0.79
3.18 3.18 1.14 1.12 0.41 94.00 0.80
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Table 2: Estimated Sample size (Nˆ ) and the Monte Carlo estimated power (Pˆ ) at β = 0.2 and α = 0.05, based on
hypothesis test of H0 : µd1 = µd3 versus H1 : µd1 6= µd3 , under different absolute value of effect size (| δd1−d3 |)
with the corresponding Monte Carlo effect size (| δˆd1−d3 |), standard deviation (ESD(δd1−d3)) and Monte Carlo
standard deviation (MCSD(δd1−d3)), absolute value of standardized effect size (| δ∗d1−d3 |) and treatments ‘3’
response rate(γd1), skewness parameter (λ) and degree of freedom (ν), given treatment ‘8’ response rate γd5 = 0.5,
σ1 = 0.95, σ0 = 1, ρ = 0.975, τ = 0.85, expected % available teeth per patient pi = 80%.
| δd1−d3 | | δˆd1−d3 | λ ν γd1 ESD(δd1−d3 ) MCSD(δd1−d3 ) | δ∗d1−d3 | Nˆ Pˆ
1.13 1.12 0 Inf 0.25 0.40 0.40 0.36 121.00 0.80
3.38 3.41 1.20 1.20 0.45 77.00 0.81
0.75 0.74 0.5 0.27 0.27 0.27 223.00 0.80
2.25 2.26 0.80 0.81 0.33 141.00 0.80
1.13 1.12 2 0.25 0.40 0.40 0.26 241.00 0.79
3.37 3.40 1.20 1.22 0.39 105.00 0.80
0.75 0.75 0.5 0.27 0.27 0.19 432.00 0.80
2.25 2.23 0.80 0.80 0.29 190.00 0.78
1.13 1.13 10 0.25 0.40 0.40 0.25 258.00 0.80
3.37 3.34 1.20 1.18 0.38 108.00 0.79
0.75 0.75 0.5 0.27 0.27 0.18 461.00 0.80
2.25 2.22 0.80 0.80 0.28 195.00 0.79
1.12 1.13 0 10 0.25 0.40 0.40 0.36 124.00 0.81
3.37 3.36 1.20 1.19 0.45 77.00 0.80
0.75 0.75 0.5 0.27 0.27 0.27 224.00 0.80
2.25 2.25 0.80 0.81 0.33 141.00 0.80
1.12 1.13 8 0.25 0.40 0.40 0.36 124.00 0.80
3.37 3.39 1.20 1.21 0.45 77.00 0.79
0.75 0.76 0.5 0.27 0.27 0.27 223.00 0.80
2.25 2.26 0.80 0.79 0.33 141.00 0.80
1.12 1.13 6 0.25 0.40 0.40 0.36 124.00 0.80
3.37 3.37 1.20 1.21 0.45 77.00 0.79
0.75 0.75 0.5 0.27 0.27 0.27 223.00 0.80
2.25 2.25 0.80 0.80 0.33 142.00 0.80
1.13 1.13 2 10 0.25 0.40 0.41 0.25 253.00 0.80
3.38 3.38 1.20 1.22 0.38 107.00 0.79
0.75 0.75 0.5 0.27 0.26 0.19 459.00 0.80
2.25 2.24 0.80 0.80 0.28 195.00 0.79
1.13 1.12 8 0.25 0.40 0.40 0.25 257.00 0.79
3.38 3.36 1.20 1.20 0.38 108.00 0.79
0.75 0.75 0.5 0.27 0.27 0.19 459.00 0.80
2.25 2.26 0.80 0.80 0.28 196.00 0.80
1.13 1.12 6 0.25 0.40 0.40 0.24 265.00 0.79
3.37 3.36 1.20 1.19 0.38 109.00 0.80
0.75 0.75 0.5 0.27 0.27 0.18 472.00 0.80
2.25 2.26 0.80 0.82 0.28 199.00 0.80
1.13 1.12 10 10 0.25 0.40 0.40 0.24 273.00 0.80
3.37 3.34 1.20 1.20 0.38 111.00 0.79
0.75 0.74 0.5 0.27 0.27 0.18 484.00 0.79
2.25 2.25 0.80 0.80 0.28 202.00 0.80
1.12 1.12 8 0.25 0.40 0.41 0.24 278.00 0.80
3.37 3.38 1.20 1.21 0.38 112.00 0.80
0.75 0.75 0.5 0.27 0.27 0.18 491.00 0.79
2.25 2.25 0.80 0.81 0.28 203.00 0.79
1.13 1.13 6 0.25 0.40 0.41 0.23 286.00 0.81
3.38 3.37 1.20 1.22 0.37 113.00 0.79
0.75 0.75 0.5 0.27 0.27 0.18 509.00 0.79
2.25 2.23 0.80 0.79 0.28 206.00 0.79
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Table 3: Estimated Sample size (Nˆ ) and the Monte Carlo estimated power (Pˆ ) at β = 0.2 and α = 0.05, based on
hypothesis test of H0 : µd1 = µd5 versus H1 : µd1 6= µd5 , under different absolute value of effect size (| δd1−d5 |)
with the corresponding Monte Carlo effect size (| δˆd1−d5 |), standard deviation (ESD(δd1−d5)) and Monte Carlo
standard deviation (MCSD(δd1−d5)), absolute value of standardized effect size (| δ∗d1−d5 |) and treatments ‘3’
response rate(γd1), skewness parameter (λ) and degree of freedom (ν), given treatment ‘8’ response rate γd5 = 0.5,
σ1 = 0.95, σ0 = 1, ρ = 0.975, τ = 0.85, expected % available teeth per patient pi = 80%.
| δd1−d5 | | δˆd1−d5 | λ ν γd1 ESD(δd1−d5 ) MCSD(δd1−d5 ) | δ∗d1−d5 | Nˆ Pˆ
0.63 0.63 0 Inf 0.25 0.22 0.22 0.20 408.00 0.81
2.12 2.13 0.76 0.76 0.28 197.00 0.80
0.75 0.75 0.5 0.27 0.27 0.26 232.00 0.79
2.25 2.23 0.80 0.80 0.33 142.00 0.79
0.62 0.63 2 0.25 0.22 0.22 0.14 789.00 0.80
2.12 2.12 0.76 0.77 0.24 264.00 0.80
0.75 0.75 0.5 0.27 0.27 0.19 448.00 0.80
2.25 2.25 0.80 0.80 0.29 192.00 0.80
0.63 0.63 10 0.25 0.23 0.23 0.14 824.00 0.79
2.12 2.12 0.76 0.74 0.24 272.00 0.80
0.75 0.75 0.5 0.27 0.27 0.18 480.00 0.80
2.25 2.25 0.80 0.80 0.28 198.00 0.80
0.62 0.63 0 10 0.25 0.22 0.22 0.20 413.00 0.80
2.13 2.10 0.76 0.75 0.28 196.00 0.79
0.75 0.75 0.5 0.27 0.27 0.26 235.00 0.79
2.25 2.24 0.80 0.80 0.33 143.00 0.79
0.63 0.63 8 0.25 0.22 0.23 0.20 411.00 0.80
2.12 2.14 0.76 0.76 0.28 197.00 0.80
0.75 0.75 0.5 0.27 0.27 0.26 235.00 0.79
2.25 2.24 0.80 0.80 0.33 143.00 0.79
0.63 0.63 6 0.25 0.22 0.22 0.20 412.00 0.80
2.12 2.14 0.76 0.76 0.28 197.00 0.80
0.75 0.75 0.5 0.27 0.27 0.26 235.00 0.79
2.25 2.25 0.80 0.80 0.33 143.00 0.79
0.62 0.63 2 10 0.25 0.22 0.22 0.14 838.00 0.81
2.13 2.12 0.76 0.77 0.24 269.00 0.79
0.75 0.75 0.5 0.27 0.27 0.18 477.00 0.80
2.25 2.25 0.80 0.80 0.28 197.00 0.80
0.63 0.63 8 0.25 0.22 0.23 0.14 835.00 0.80
2.12 2.13 0.76 0.74 0.24 273.00 0.81
0.75 0.75 0.5 0.27 0.27 0.18 478.00 0.80
2.25 2.25 0.80 0.82 0.28 198.00 0.79
0.63 0.63 6 0.25 0.22 0.22 0.14 859.00 0.80
2.13 2.11 0.76 0.76 0.24 275.00 0.78
0.75 0.76 0.5 0.27 0.27 0.18 491.00 0.81
2.25 2.25 0.80 0.80 0.28 201.00 0.80
0.63 0.62 10 10 0.25 0.22 0.22 0.13 890.00 0.80
2.12 2.13 0.76 0.76 0.24 280.00 0.80
0.75 0.76 0.5 0.27 0.27 0.18 507.00 0.80
2.25 2.25 0.80 0.81 0.28 203.00 0.80
0.63 0.62 8 0.25 0.22 0.22 0.13 900.00 0.79
2.12 2.14 0.76 0.76 0.24 282.00 0.80
0.75 0.75 0.5 0.27 0.26 0.17 519.00 0.80
2.25 2.25 0.80 0.82 0.28 205.00 0.79
0.63 0.63 6 0.25 0.22 0.22 0.13 935.00 0.80
2.13 2.13 0.76 0.76 0.23 286.00 0.80
0.75 0.75 0.5 0.27 0.27 0.17 532.00 0.80
2.25 2.25 0.80 0.80 0.27 209.00 0.80
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5 Implementation in R
In this section, we demonstrate the implementation of the R function SampleSize.SMARTp for sample size
calculations via a simulation study. The function is currently available for ready use via the GitHub link https:
//github.com/bandyopd/SMARTp, and forthcoming in the CRAN repository as a R package SMARTp. The
current version of this function only considers a two-stage SMART design.
Figure 2 defines the SMART design. The first three inputs of the function SampleSize.SMARTp(mu,
st1, dtr, regime, pow, b, a, rho, tau, sigma1, lambda, nu, sigma0, Num, p i, c i,
a0, b0, cutoff) are matrices, defined as:
• mu: mean matrix, where rows represent treatment paths and columns represents cluster sub-units (i.e. teeth)
within a cluster (mouth),
• st1: stage-1 treatment matrix, where rows represent the corresponding stage-1 treatments, the 1st column
includes the numbers of treatment options for responder, the 2nd column includes the numbers of treatment
options for non-responders, the 3rd column are the response rates, and the 4th column includes the row
numbers of matrix ‘st1’,
• dtr: matrix of dimension (# of DTRs X 4), the 1st column represents the DTR numbers, the 2nd column
represents the corresponding treatment path numbers of responders for the corresponding DTRs in the 1st
column, the third column represents the corresponding treatment path numbers of the non-responders for the
corresponding DTRs in the 1st column, while the 4th column represents the corresponding initial treatment.
The regime can be, a vector of two regime numbers if the hypothesis test is to compare regimes, or a single
regime number if the hypothesis test is to detect the effect of that regime. The power, type-2 and type-1 error rates,
given by pow, b and a respectively, with the corresponding defaults 0.8, 0.2 and 0.05. The parameters τ and ρ,
which quantifies the variation and association in the CAR specification of the random effect Qit are given by tau
and rho, respectively, with defaults set at tau = 0.85 and rho = 0.975. The inputs sigma1, lambda and nu
define the scale (σ1), skewness (λ) and degrees of freedom (ν) parameters of the residual it1, which defaults to
sigma1 = 0.95, lambda = 0 and nu = Inf. The standard deviation σ0 for the residual it0 is given by sigma0,
whose default is sigma0 = 1. The rest of the parameters a0, b0 and c0 from (2) are specified by a0, b0 and
cutoff respectively, and their defaults are a0 = -1, b0 = 0.5 and cutoff = 0. The user can either provide the
choice of a0 and b0, or the choice p i and c i, which are the expected proportion pi of available teeth for patient
i, and the average Pearson’s correlation coefficient ci between Yit and Mit0, averaged over the 28 teeth for patient
i, respectively.
19
Monte Carlo estimates of the mean and variance of Y¯i for each treatment path were obtained using Num random
samples.
The possible outputs are summarized below:
• N, the calculated sample size,
• Sigma, the CAR covariance matrix of Qit, i.e. Σ28×28,
• ybard1, the regime mean corresponding to the 1st element of regime, which is µd1 if, for example,
regime = c(1, 5),
• ybard2, the regime mean corresponding to the 2nd element of regime, which is µd5 if, for example,
regime = c(1, 5); 0, if regime = c(1),
• sig.d1.sq, N×the variance of the estimated regime mean corresponding to the 1st element of regime,
which is NVAR(Y¯ d1) if, for example, regime = c(1, 5),
• sig.d2.sq, N×the variance of the estimated regime mean corresponding to the 2nd element of regime,
which is NVAR(Y¯ d5) if, for example, regime = c(1, 5), or 0 if regime = c(1),
• sig.d1d2, N×the covariance between the estimated regime means correspond to regime, which is
NCOV(Y¯ d1 , Y¯ d5) if, for example, regime = c(1, 5), or 0 if regime = c(1),
• sig.e.sq, N×the variance of the difference between the estimated regime means correspond to regime,
which is NVAR(Y¯ d1 − Y¯ d5) if for example, regime = c(1, 5), or NVAR(Y¯ d1) if regime = c(1),
• Del, absolute value of the effect size, which is | δd1−d5 |=| µd1-µd5 | if, for example, regime = c(1,5), or
| δd1 |=| µd1 |, if regime = c(1),
• Del std, absolute value of the standardized effect size, | δ?d1−d5 |=| δd1−d5 | /
√
VAR(Y¯ d1 − Y¯ d5)/2 if,
for example, regime = c(1,5),
• p st1, randomization probability of stage-1 for each treatment path,
• p st2, randomization probability of stage-2 for each treatment path,
• res, a vector with binary indicators denoting responders and non-responders that corresponds to a treatment
path,
• ga, response rates of initial treatments corresponding to each treatment path,
• initr, a vector with dimension as the number of treatment paths, whose elements are the corresponding
row number of st1.
20
In the following, we present the R codes for the sample size calculation corresponding to the second row of Table
3 in Section 4.
# The SMART Design
mu=matrix ( 0 , 1 0 , 2 8 ) ; mu[ 2 , ] = rep ( 0 . 5 , 2 8 ) ; mu[ 4 , ] = rep ( 2 , 2 8 ) ; mu[ 7 , ] = rep ( 5 , 2 8 ) ;
s t 1 =cbind ( c ( 1 , 1 ) , c ( 4 , 4 ) , c ( 0 . 2 5 , 0 . 5 ) , 1 : 2 ) ;
d t r =cbind ( 1 : 8 , c ( rep ( 1 , 4 ) , rep ( 6 , 4 ) ) , c ( 2 , 3 , 4 , 5 , 7 , 8 , 9 , 1 0 ) , c ( rep ( 1 , 4 ) , rep ( 2 , 4 ) ) )
## H y p o t h e s i s T e s t 3 , w i t h power , Type−1 and Type−2 e r r o r r a t e s t o be 80%, 5%
## and 20% r e s p e c t i v e l y
r eg ime =c ( 1 , 5 ) ; pow = 0 . 8 ; b = 1−pow ; a = 0 . 0 5
## Parameter v a l u e s
c u t o f f =0 ; s igma1 = 0 . 9 5 ; s igma0 =1; lambda =0; nu= I n f ; b0 = 0 . 5 ; a0 =−1.0; rho = 0 . 9 7 5 ;
t a u = 0 . 8 5 ; p i =0 . 80 2 78 7 2 ; c i =0 .4125813
## I t e r a t i o n s i z e
Num = 1000000
Then, the R codes to compute N , δd1−d5 , VAR(Y¯ d1 − Y¯ d5), δ?d1−d5 , VAR(Y¯ d1), VAR(Y¯ d5) and COV(Y¯ d1 , Y¯ d5)
are respectively:
SampleS ize = SampleS ize . SMARTp(mu=mu , s t 1 = s t 1 , d t r = d t r , r eg ime =regime , pow=pow , b=b ,
a=a , rho =rho , t a u = tau , s igma1=sigma1 , lambda=lambda , nu=nu , s igma0=sigma0 ,
Num=Num, p i =p i , c i =c i , c u t o f f = c u t o f f ) ;
N= c e i l i n g ( SampleS ize $N ) ; N;
Del= SampleS ize $Del ; Del ;
s i g . e . sq= SampleS ize $ s i g . e . sq ; s i g . e . sq /N;
Del s t d =Del / s q r t ( s i g . e . sq / 2 ) ; Del s t d ;
s i g . d1 . sq= SampleS ize $ s i g . d1 . sq ; s i g . d1 . sq /N;
s i g . d2 . sq= SampleS ize $ s i g . d2 . sq ; s i g . d2 . sq /N;
s i g . d1d2= SampleS ize $ s i g . d1d2 ; s i g . d1d2 /N.
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6 Discussion
This paper proposes a two-stage SMART design to study a number of DTRs for managing CP. A statistical analysis
plan under this design includes hypothesis testing of detecting an effect size for either a single regime, or the
difference between two regimes with or without sharing an initial treatment. This paper also develops a novel
sample size calculation method, accommodating typical statistical challenges observed in CP data, such as non-
Gaussianity, spatial association, and non-random misingness. To the best of our knowledge, this is the first SMART
proposal in CP research within the umbrella of precision oral health – a major goal in the NIH/NIDCR’s Strategic
Plan 2014-2019, and advances previous SMART proposals (Ghosh et al., 2016; NeCamp et al., 2017) considered
for clustered data.
An appealing feature of our method is the availability of R codes for implementation. However, with precision
oral health as a recently emerging field, there are no real data to support the input information in the proposed
sample size formula. We recommend considering plausible assumptions, such as medium effect size, conservative
sample sizes, etc, to come up with the input values for implementing our proposed SMART design. Additionally,
they can be referenced by estimates from existing single-stage clinical trials. However, our experimental design,
statistical analysis plan or sample size calculation can be updated or improved through data collection.
Similar to Oetting et al. (2011), the proposed sample size method can also be extended to determine the optimal
treatment regime. Our method can be easily updated to include more therapies (such as, various kinds of laser),
and the number of treatment stages (which leads to close monitoring of CAL changes), with each stage considering
more treatment types. Also, by using the Q-function approach that minimizes squared error (NeCamp et al., 2017),
or maximizing likelihood (Van Der Laan and Rubin, 2006), the effect size of DTRs can be adjusted by adding
baseline characteristics, such as age, gender, education, oral hygiene, etc, into the regression models (1) or (2).
These are important avenues for future research, and will be considered elsewhere.
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Appendix
A Skew-normal distribution
The statistical properties and the application of skew-normal distribution are described in Azzalini and Dalla Valle
(1996) and Azzalini and Capitanio (1999) respectively. Aparecida Guedes et al. (2014) presents an example of
applying a regression model with skew-normal errors. Here, we present a brief introduction.
Define Z0 ∼ N(0, 1), independent of a m-dimensional random variable Z = (Z1, . . . , Zm)> with standard-
ized normal marginals, and correlation matrix Ψ. Suppose κ1, . . . , κm ∈ (−1, 1), define
Xj = κj | Z0 | +(1− κ2j )1/2Zj , (A-1)
for j = 1, . . . ,m, where κj = λj/(1 + λ2j )
1/2, such that Xj ∼ SN(λj), where ‘SN’ stands for skew-normal
and λ ∈ (−∞,∞) controls skewness. The probability density function of Xj is f(xj ;λj) = 2φ(xj)Φ(λjxj), for
−∞ < xj < ∞, where φ(·) and Φ(·) denote the density and cumulative distribution function (cdf) of N(0, 1),
respectively. The joint density function of X1, . . . , Xm is given by
f(x;θx,Ωx) = 2φm(x; Ωx)Φ(θ
>
x x), (A-2)
where x = (x1, . . . , xm)>, φm(x; Ωx) denotes the density function of the m-dimension multivariate normal
distribution with standardized marginals and correlation matrix Ωx. We have θ>x =
λ>Ψ−1K−1
(1 + λ>Ψ−1λ)1/2
, K =
diag((1− κ21)1/2, . . . , (1− κ2m)1/2), and Ωx = K(Ψ + λλ>)K.
Define Y = ξ + ωX , with Y = (Y1, . . . Ym)>, ξ = (ξ1, . . . ξm)> and ω = diag(ω1, . . . ωm)>, where the
components of ω are assumed to be positive. The density function of Y is
f(y; ξ,Ω,θ) = 2φm(y − ξ; Ω)Φ(θ>(y − ξ)), (A-3)
where Ω = ωΩxω and θ> = θ>xω−1. Thus, Y is the m-dimensional random variable from the SN distribution,
with location ξ, scale ω and skewness θ, i.e. Y ∼ SNm(ξ,Ω,θ). From (A-3), we have E(Y ) = ξ+ω
(
2
pi
)1/2
κ,
V AR(Y ) = Ω− ω2 2piκκ>, and the skewness vector SKEW (Y ) = 4−pi2
(κ
√
2/pi)3
(1−2κ2/pi)3/2 = γ1
B Skew-t distribution
Skew-t random variables generated from both the skew-normal and Chi-squared variables are described in Azzalini
and Capitanio (2003b). Here, W ∼ STm(ξ,Ω,θ, ν), such that W = ξ + ωX/
√
V and ωX ∼ SNm(0,Ω,θ),
where V ∼ χ2ν/ν is independent ofX .
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The density function ofW is
fW (w; ξ,Ω,θ, ν) = 2tm(w; ξ,Ω,θ, ν)T1
(
θ>(w − ξ)
√
ν +m
Qw + ν
; ν +m
)
, (B-1)
where Qw = (Y − ξ)>Ω−1(Y − ξ), tm(·; ξ,Ω,θ, ν) denotes the density function of a m-dimensional t variate
with location ξ, shape matrix Ω and degrees of freedom ν, while T1(·; ν + m) denotes the cdf of an univariate
student’s t with degrees of freedom ν +m. We can use the expression Y = ξ + ωX to compute the moments of
Y, i.e. the n-th moment of Y is
E(Y n) = E(Xn)E(V −n/2), (B-2)
where
E(V −n/2) =
(ν/2)n/2Γ(12(ν − n))
Γ(12ν)
with E(Xn) given in Azzalini and Capitanio (1999). Thus, the mean and variance, are, respectively,
E(W ) = ξ + ωκ(ν/pi)1/2
Γ(12(ν − 1))
Γ(12ν)
, ν > 1,
var(W ) =
ν
ν − 2Ω−
ν
pi
(
Γ(12(ν − 1))
Γ(12ν)
)2
ω2κκ>, ν > 2,
Similarly, the skewness (γ1) and kurtosis (γ2) for the univariate cases are
γ1 = µ
[
ν(3− κ2)
ν − 3 −
3ν
ν − 2 + 2µ
2
] [
ν
ν − 2 − µ
2
]−3/2
, ν > 3,
γ2 =
[
3ν2
(ν − 2)(ν − 4) −
4µ2ν(3− κ2)
ν − 3 +
6µ2ν
ν − 2 − 3µ
4
] [
ν
ν − 2 − µ
2
]−2
− 3, ν > 4,
where µ = κ
√
ν
pi
Γ(12(ν − 1))
Γ(12ν)
.
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C Sample size formula derivation
The covariance between Yit and Mit0 is
COV(µi +Qit + it1, a0 + b0Qit + it0)
=COV(Qit, b0Qit)
=b0VAR(Qit)
=b0Σtt,
where Σtt is the tth diagonal elements of the covariance matrix Σ28×28. The Pearson correlation coefficient is
cit =
b0VAR(Qit)√
VAR(µi +Qit + it1)VAR(a0 + b0Qit + it0)
=
b0VAR(Qit)√
(VAR(Qit) + VAR(it1))(b20VAR(Qit) + VAR(it0))
,
where VAR(Qit) = Σtt, VAR(it0) = σ20 and VAR(it1) =
σ21ν
ν−2 -
ν
pi
[
Γ(0.5(ν−1))
Γ(0.5ν)
]2 σ21λ2
1+λ2
if ν < ∞, otherwise
VAR(it1)=σ21 -
2
pi
σ21λ
2
1+λ2
. Now, we derive an expression for pi, i.e.,
pi =1− E
(∑28
t=1Mit
28
)
=1− 1
28
28∑
t=1
E [E(Mit | Qit, it0)]
=1− 1
28
28∑
t=1
E [E(I(a0 + b0Qit + it0 > c0) | Qit, it0)]
=1− 1
28
28∑
t=1
E [I(a0 + b0Qit + it0 > c0)]
=1− 1
28
28∑
t=1
Pr(a0 + b0Qit + it0 > c0)
=1− 1
28
28∑
t=1
Pr
(
z >
c0 − E(a0 + b0Qit + it0)√
VAR(a0 + b0Qit + it0)
)
=1− 1
28
28∑
t=1
[
1− Φ
(
c0 − a0√
b20Σtt + σ
2
0
)]
where Φ(·) is the cdf of z ∼N(0,1). Now,
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E(Y¯ d1) =E
(
I(Ai1 = a
d1
1i , Ai2 = [a
d1R
2i ]
Ri [ad1NR2i ]
1−Ri)
pid11i [pi
d1R
2i ]
Ri [pid1NR2i ]
1−Ri
Y¯i
)
=E
[
E
(
I(Ai1 = a
d1
1i , Ai2 = [a
d1R
2i ]
Ri [ad1NR2i ]
1−Ri)
pid11i [pi
d1R
2i ]
Ri [pid1NR2i ]
1−Ri
Y¯i | Ri
)]
=γd1µd1R + (1− γd1)µd1NR.
In a similar way, we have E(Y¯ d3) = γd3µd3R + (1− γd3)µd3NR.
According to variance decomposition, the right side of (8) is the sum of two components, which are
E[V (
I(Ai1 = a
d1
1i , Ai2 = [a
d1R
2i ]
Ri [ad1NR2i ]
1−Ri)
pid11i [pi
d1R
2i ]
Ri [pid1NR2i ]
1−Ri
Y¯i | Ri)]
and
V [E(
I(Ai1 = a
d1
1i , Ai2 = [a
d1R
2i ]
Ri [ad1NR2i ]
1−Ri)
pid11i [pi
d1R
2i ]
Ri [pid1NR2i ]
1−Ri
Y¯i | Ri)].
The first component is
E[V (
I(Ai1 = a
d1
1i , Ai2 = [a
d1R
2i ]
Ri [ad1NR2i ]
1−Ri)
pid11i [pi
d1R
2i ]
Ri [pid1NR2i ]
1−Ri
Y¯i | Ri)]
=
1∑
Ri=0
V (
I(Ai1 = a
d1
1i , Ai2 = [a
d1R
2i ]
Ri [ad1NR2i ]
1−Ri)
pid11i [pi
d1R
2i ]
Ri [pid1NR2i ]
1−Ri
Y¯i | Ri)Pr(Ri),
while the second component is
V [E(
I(Ai1 = a
d1
1i , Ai2 = [a
d1R
2i ]
Ri [ad1NR2i ]
1−Ri)
pid11i [pi
d1R
2i ]
Ri [pid1NR2i ]
1−Ri
Y¯i | Ri)]
=
1∑
Ri=0
E2(
I(Ai1 = a
d1
1i , Ai2 = [a
d1R
2i ]
Ri [ad1NR2i ]
1−Ri)
pid11i [pi
d1R
2i ]
Ri [pid1NR2i ]
1−Ri
Y¯i | Ri)Pr(Ri)
− (
1∑
Ri=0
E(
I(Ai1 = a
d1
1i , Ai2 = [a
d1R
2i ]
Ri [ad1NR2i ]
1−Ri)
pid11i [pi
d1R
2i ]
Ri [pid1NR2i ]
1−Ri
Y¯i | Ri)Pr(Ri))2,
based on the formulae E(X) = E[E(X | Y )] and V (X) = E(X2) − E2(X). We have Pr(Ri = 1) = γd1 or
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Pr(Ri = 0) = 1− γd1 , and
V (
I(Ai1 = a
d1
1i , Ai2 = [a
d1R
2i ])
pid11i [pi
d1R
2i ]
Y¯i | Ri = 1)
=E(
I(Ai1 = a
d1
1i , Ai2 = [a
d1R
2i ])
(pid11i [pi
d1R
2i ])
2
Y¯ 2i )− E2(
I(Ai1 = a
d1
1i , Ai2 = [a
d1R
2i ])
pid11i [pi
d1R
2i ]
Y¯i)
=
1
pid11i [pi
d1R
2i ]
Ed1R(Y¯
2
i )− E2d1R(Y¯i)
=
1
pid11i [pi
d1R
2i ]
(σ2d1R + (1− pid11i [pid1R2i ])µ2d1R),
with µd1R, the expectation of Y¯i from d1, with Ri = 1, given by
Ed1R(Y¯i)
=Ed1R
(
Ed1R
(∑28
t=1 Yit(1−Mit)∑28
t=1(1−Mit)
| Qi, i0
))
=Ed1R
(
Ed1R
(∑28
t=1(µi +Qit + it1)(1− I(a0 + b0Qit + it0 > 0))∑28
t=1(1− I(a0 + b0Qit + it0 > 0))
| Qi, i0
))
=E
(∑28
t=1(µi |Ai3=1,Ri=1 +Qit + E(it1))(1− I(a0 + b0Qit + it0 > 0))∑28
t=1(1− I(a0 + b0Qit + it0 > 0))
)
=
∫
Qi
∫
i
∑28
t=1(µi |Ai3=1,Ri=1 +Qit + E(it1))(1− I(a0 + b0Qit + it0 > 0))∑28
t=1(1− I(a0 + b0Qit + it0 > 0))
f(Qi)f(i)didQi,
where f(Qi) and f(i) are the density functions for Qi and i respectively. Also, σ
2
d1R
, the variance of Y¯i that is
from d1, with Ri = 1, can be written as
Vd1R(Y¯i) = Ed1R(Vd1R(Y¯i | Qi, i0)) + Vd1R(Ed1R(Y¯i | Qi, i0)),
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where
Ed1R(Vd1R(Y¯i | Qi, i0))
=Ed1R
(
Vd1R
(∑28
t=1 Yit(1−Mit)∑28
t=1(1−Mit)
| Qi, i0
))
=E
(
V
(∑28
t=1(µi |Ai3=1,Ri=1 +Qit + it1)(1− I(a0 + b0Qit + it0 > 0))∑28
t=1(1− I(a0 + b0Qit + it0 > 0))
))
=E
 ∑28t=1[1− I(a0 + b0Qit + it0 > 0)]σ21(∑28
t=1[1− I(a0 + b0Qit + it0 > 0)]
)2

=
∫
Qi
∫
i
∑28
t=1[1− I(a0 + b0Qit + it0 > 0)]σ21(∑28
t=1[1− I(a0 + b0Qit + it0 > 0)]
)2 f(Qi)f(i)didQi
and
Vd1R(Ed1R(Y¯i | Qi, i0))
=Vd1R
(
Ed1R
(∑28
t=1 Yit(1−Mit)∑28
t=1(1−Mit)
| Qi, i0
))
=V
(
E
(∑28
t=1(µi |Ai3=1,Ri=1 +Qit + it1)(1− I(a0 + b0Qit + it0 > 0))∑28
t=1(1− I(a0 + b0Qit + it0 > 0))
))
=V
(∑28
t=1(µi |Ai3=1,Ri=1 +Qit + E(it1))(1− I(a0 + b0Qit + it0 > 0))∑28
t=1(1− I(a0 + b0Qit + it0 > 0))
)
=E
(∑28t=1(µi |Ai3=1,Ri=1 +Qit + E(it1))(1− I(a0 + b0Qit + it0 > 0))∑28
t=1(1− I(a0 + b0Qit + it0 > 0))
)2
−
[
E
(∑28
t=1(µi |Ai3=1,Ri=1 +Qit + E(it1))(1− I(a0 + b0Qit + it0 > 0))∑28
t=1(1− I(a0 + b0Qit + it0 > 0))
)]2
=
∫
Qi
∫
i
(∑28
t=1(µi |Ai3=1,Ri=1 +Qit + E(it1))(1− I(a0 + b0Qit + it0 > 0))∑28
t=1(1− I(a0 + b0Qit + it0 > 0))
)2
f(Qi)f(i)didQi
−
[∫
Qi
∫
i
∑28
t=1(µi |Ai3=1,Ri=1 +Qit + E(it1))(1− I(a0 + b0Qit + it0 > 0))∑28
t=1(1− I(a0 + b0Qit + it0 > 0))
f(Qi)f(i)didQi
]2
.
Similarly, we have
V (
I(Ai1 = a
d1
1i , Ai2 = [a
d1NR
2i ])
pid11i [pi
d1NR
2i ]
Y¯i | Ri = 0) = 1
pid11i [pi
d1NR
2i ]
(σ2d1NR + (1− pid11i [pid1NR2i ])µ2d1NR)
28
, where µ2d1NR and σ
2
d1NR
are the expectation and variance of Y¯i from d1 with Ri = 0.
Therefore, the second component is
V [E(
I(Ai1 = a
d1
1i , Ai2 = [a
d1R
2i ]
Ri [ad1NR2i ]
1−Ri)
pid11i [pi
d1R
2i ]
Ri [pid1NR2i ]
1−Ri
Y¯i | Ri)]
=γd1µ2d1R + (1− γd1)µ2d1NR − (γd1µd1R + (1− γd1)µd1NR)2
=γd1(1− γd1)(µd1R − µd1NR)2.
Thus, the variance formula (8) is
V (Y¯ d1)
=
1
N
{ γ
d1
pid11i [pi
d1R
2i ]
(σ2d1R + (1− pid11i [pid1R2i ])µ2d1R) +
1− γd1
pid11i [pi
d1NR
2i ]
(σ2d1NR + (1− pid11i [pid1NR2i ])µ2d1NR)+
γd1(1− γd1)(µd1R − µd1NR)2}
while V (Y¯ d3) is
1
N
{ γ
d3
pid31i [pi
d3R
2i ]
(σ2d3R + (1− pid31i [pid3R2i ])µ2d3R) +
1− γd3
pid31i [pi
d3NR
2i ]
(σ2d3NR + (1− pid31i [pid3NR2i ])µ2d3NR)+
γd3(1− γd3)(µd3R − µd3NR)2}.
The variance of the difference between d1 and d3 is
V (Y¯ d1 − Y¯ d3) = V (Y¯ d1) + V (Y¯ d3)− 2COV(Y¯ d1 , Y¯ d3). (C-1)
29
The covariance between Y¯ d1 and Y¯ d3 is
COV
(
Y¯ d1 , Y¯ d3
)
=
1
N2
COV
(
N∑
i=1
W d1i Y¯i,
N∑
i=1
W d3i Y¯i
)
=
1
N2
COV
(
N∑
i=1
W d1i Y¯i(Ri + (1−Ri)),
N∑
i=1
W d3i Y¯i(Ri + (1−Ri))
)
=
1
N2
COV
(
N∑
i=1
W d1i Y¯iRi +W
d1
i Y¯i(1−Ri),
N∑
i=1
W d3i Y¯iRi +W
d3
i Y¯i(1−Ri)
)
=
1
N2
COV
(
N∑
i=1
W d1i Y¯iRi +
N∑
i=1
W d1i Y¯i(1−Ri),
N∑
i=1
W d3i Y¯iRi +
N∑
i=1
W d3i Y¯i(1−Ri)
)
=
1
N2
COV
(
N∑
i=1
W d1i Y¯iRi,
N∑
i=1
W d3i Y¯iRi
)
+
1
N2
COV
(
N∑
i=1
W d1i Y¯iRi,
N∑
i=1
W d3i Y¯i(1−Ri)
)
+
1
N2
COV
(
N∑
i=1
W d1i Y¯i(1−Ri),
N∑
i=1
W d3i Y¯iRi
)
+
1
N2
COV
(
N∑
i=1
W d1i Y¯i(1−Ri),
N∑
i=1
W d3i Y¯i(1−Ri)
)
=
1
N2
 N∑
i=1
COV
(
W d1i Y¯iRi,W
d3
i Y¯iRi
)
+
∑
i 6=j
COV
(
W d1i Y¯iRi,W
d3
j Y¯jRj
)
+
1
N2
 N∑
i=1
COV
(
W d1i Y¯iRi,W
d3
i Y¯i(1−Ri)
)
+
∑
i 6=j
COV
(
W d1i Y¯iRi,W
d3
j Y¯j(1−Rj)
)
+
1
N2
 N∑
i=1
COV
(
W d1i Y¯i(1−Ri),W d3i Y¯iRi
)
+
∑
i 6=j
COV
(
W d1i Y¯i(1−Ri),W d3j Y¯jRj
)
+
1
N2
 N∑
i=1
COV
(
W d1i Y¯i(1−Ri),W d3i Y¯i(1−Ri)
)
+
∑
i 6=j
COV
(
W d1i Y¯i(1−Ri),W d3j Y¯j(1−Rj)
)
=
1
N
COV
(
W d1i Y¯iRi,W
d3
i Y¯iRi
)
+
1
N
COV
(
W d1i Y¯iRi,W
d3
i Y¯i(1−Ri)
)
+
1
N
COV
(
W d1i Y¯i(1−Ri),W d3i Y¯iRi
)
+
1
N
COV
(
W d1i Y¯i(1−Ri),W d3i Y¯i(1−Ri)
)
,
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where
COV
(
W d1i Y¯iRi,W
d3
i Y¯iRi
)
=E(W d1i Y¯iRiW
d3
i Y¯iRi)− E(W d1i Y¯iRi)E(W d3i Y¯iRi)
=E[E(W d1i Y¯iRiW
d3
i Y¯iRi) | Ri]− E[E(W d1i Y¯iRi) | Ri]E[E(W d3i Y¯iRi) | Ri]
=
γd1
pid11i pi
d1R
2i
Ed1R(Y¯
2
i )
− γd1γd3Ed1R(Y¯i)Ed3R(Y¯i)
=
γd1
pid11i pi
d1R
2i
[
σ2d1R + µ
2
d1R
]− γd1γd3µd1Rµd3R,
Similarly,
COV
(
W d1i Y¯iRi,W
d3
i Y¯i(1−Ri)
)
=E[E(W d1i Y¯iRiW
d3
i Y¯i(1−Ri)) | Ri]− E[E(W d1i Y¯iRi) | Ri]E[E(W d3i Y¯i(1−Ri)) | Ri]
=− γd1(1− γd3)µd1Rµd3NR,
COV
(
W d1i Y¯i(1−Ri),W d3i Y¯iRi
)
=E[E(W d1i Y¯i(1−Ri)W d3i Y¯iRi) | Ri]− E[E(W d1i Y¯i(1−Ri)) | Ri]E[E(W d3i Y¯iRi) | Ri]
=− γd3(1− γd1)µd1NRµd3R,
COV
(
W d1i Y¯i(1−Ri),W d3i Y¯i(1−Ri)
)
=E[E(W d1i Y¯i(1−Ri)W d3i Y¯i(1−Ri)) | Ri]− E[E(W d1i Y¯i(1−Ri)) | Ri]E[E(W d3i Y¯i(1−Ri)) | Ri]
=− (1− γd1)(1− γd3)µd1NRµd3NR.
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Thus, COV
(
Y¯ d1 , Y¯ d3
)
is
COV
(
Y¯ d1 , Y¯ d3
)
=
1
N
{ γ
d1
pid11i pi
d1R
2i
(σ2d1R + µ
2
d1R)− γd1γd3µd1Rµd3R
− γd1(1− γd3)µd1Rµd3NR
− γd3(1− γd1)µd1NRµd3R
− (1− γd1)(1− γd3)µd1NRµd3NR}.
Therefore, the variance of regime means differences between d1 and d3 is
V (Y¯ d1 − Y¯ d3)
=
1
N
{ γ
d1
pid11i [pi
d1R
2i ]
(σ2d1R + (1− pid11i [pid1R2i ])µ2d1R)+
1− γd1
pid11i [pi
d1NR
2i ]
(σ2d1NR + (1− pid11i [pid1NR2i ])µ2d1NR)+
γd1(1− γd1)(µd1R − µd1NR)2+
γd3
pid31i [pi
d3R
2i ]
(σ2d3R + (1− pid31i [pid3R2i ])µ2d3R)+
1− γd3
pid31i [pi
d3NR
2i ]
(σ2d3NR + (1− pid31i [pid3NR2i ])µ2d3NR)+
γd3(1− γd3)(µd3R − µd3NR)2
− 2[ γ
d1
pid11i pi
d1R
2i
(σ2d1R + µ
2
d1R)− γd1γd3µd1Rµd3R
− γd1(1− γd3)µd1Rµd3NR
− γd3(1− γd1)µd1NRµd3R
− (1− γd1)(1− γd3)µd1NRµd3NR]}.
Similarly, we can also derive the expression for COV
(
Y¯ d1 , Y¯ d5
)
, where d1 and d5 does not share an initial
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treatment, i.e.
COV
(
Y¯ d1 , Y¯ d5
)
=
1
N
{−γd1γd5µd1Rµd5R
− γd1(1− γd5)µd1Rµd5NR
− γd5(1− γd1)µd1NRµd5R
− (1− γd1)(1− γd5)µd1NRµd5NR}.
D Proof of Theorem 1
Proof:
The proof ofconsistency requires the result of strong law of large numbers, such that
δˆd1−d3 = Y¯d1−Y¯d3=
1
N
∑N
i=1W
d1
i Y¯i-
1
N
∑N
i=1W
d3
i Y¯i → µd10−µd30, almost surely, and uniformly for δd1−d3 ∈ Θ
asN →∞ and δ(d1−d3)0 being the unique expected value of δˆd1−d3 due to Assumption 2. To prove the asymptotic
normality result, we have
√
N(δˆd1−d3 − δ(d1−d3)0)
=
√
N
[
1
N
N∑
i=1
W d1i Y¯i −
1
N
N∑
i=1
W d3i Y¯i − (µd10 − µd30)
]
with E
(
1
N
∑N
i=1W
d1
i Y¯i
)
= µd10, E
(
1
N
∑N
i=1W
d3
i Y¯i
)
= µd30, E
(
δˆd1−d3
)
= δ(d1−d3)0 and var(δˆd1−d3) =
2σ2d1−d3/N . Thus, by the central limit theorem,
√
N(δˆd1−d3−δ(d1−d3)0) converges in distribution toN(0, 2σ2d1−d3).
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